Increased Myc gene copy number is observed in human prostate cancer. To define Myc's functional role, we generated transgenic mice expressing human c-Myc in the mouse prostate. All mice developed murine prostatic intraepithelial neoplasia followed by invasive adenocarcinoma. Microarray-based expression profiling identified a Myc prostate cancer expression signature, which included the putative human tumor suppressor NXK3.1. Human prostate tumor databases revealed modules of human genes that varied in concert with the Myc prostate cancer signature. This module includes the Pim-1 kinase, a gene known to cooperate with Myc in tumorigenesis, and defines a subset of human, "Myc-like" human cancers. This approach illustrates how genomic technologies can be applied to mouse cancer models to guide evaluation of human tumor databases.
Introduction
of Myc in human prostate cancer remains undefined. Numerous studies of human prostate cancer have demonstrated increased The mouse has long been exploited as a model to study the Myc gene copy number in up to 30% of tumors, even at the molecular basis of human cancers and test novel therapies.
preneoplastic stage called prostate intraepithelial neoplasia (PIN) (Jenkins et al., 1997; Nesbit et al., 1999; Qian et al., 1997 ; Recent advances in mouse engineering techniques and in genomics tools to query mouse tumor tissue allow a more global Sato et al., 1999) , but this finding is not conclusive because Myc is one of many genes localized to this 8q24 amplicon (Elo comparison of these models to human cancer. We have addressed this issue in a novel transgenic model of mouse prostate and Visakorpi, 2001) . Efforts to define the mechanism by which Myc induces can-cancer using the human Myc gene as the initiating event. Myc has been widely implicated in many human cancers (Nesbit et cer have identified a number of effects such as increased cell proliferation, which clearly contribute to tumorigenesis. Among al., 1999) and is sufficient to give cancer phenotypes in various murine tissues when expressed as a transgene (Jensen et al., the most perplexing has been the well-documented proapoptotic activity of Myc, particularly when serum or other survival factors 2002; Moroy et al., 1991; Nesbit et al., 1999; Pelengaris et al., 1999 Pelengaris et al., , 2002a Pelengaris et al., , 2002b Zhang et al., 2000b) . We focused our are limiting (Ahmed et al., 1997; Evan et al., 1992; Pelengaris et al., 2002b; Prendergast, 1999) . Recent transgenic models studies on the role of Myc in prostate cancer for two reasons. First, several independent, publicly available gene expression have clarified how the seemingly paradoxical death-promoting activity of Myc can lead to cancer. Expression of a hormone-profiling datasets of human prostate tumors (Dhanasekaran et al., 2001; Singh et al., 2002; Welsh et al., 2001) are available regulated Myc transgene in the skin rapidly induces epidermal hyperplasia and papillomas, with associated increases in cellu-for comparison to mouse models. Second, the functional role lar proliferation and minimal evidence of apoptosis (Pelengaris of insulin-producing islet cells, due to increased apoptosis, and subsequent onset of diabetes (Pelengaris et al., 2002a (Pelengaris et al., , 2002b (Pelengaris et al., ). et al., 1999 (Pelengaris et al., , 2002a . However, these tumors rapidly apoptose when cultured ex vivo, presumably due to the lack of critical When complemented with a BclX L transgene, the mice no longer display the apoptotic phenotype, but develop aggressive islet cell survival factors present in the mouse dermis. In contrast, transgenic expression of Myc in the pancreas causes rapid involution cancers. These experiments demonstrate that the response to Myc A: Longer latency for cancer progression in Lo-Myc mice. Dorsolateral lobes from 6 and 12 month transgenic mice reveal invasive adenocarcinoma at 12 months in the Lo-Myc animals (a-d) . In contrast, invasive tumor is already apparent by 6 months (e and g) in the Hi-Myc mice. Arrows depict nuclear atypia associated with mPIN and cancer. B: Presence of an intact fibromuscular layer and basement membrane, as shown by the positive SMA and laminin immunostaining (arrows, a and b), confirms the in situ nature of the mPIN lesions. In contrast, SMA and laminin staining are absent in the invasive tumors (c and d) . Contractile smooth muscle surrounding blood vessels serve as internal positive controls (arrows, c and d). C: Tumors do not undergo neuroendocrine differentiation. Synaptophysin immunostaining identifies the rare neuroendocrine cell normally present in murine prostates (a, arrow). The Hi-Myc prostate with invasive adenocarcinoma shows no synaptophysin staining (b) whereas the dorsolateral lobes of the LADY mice stain positive (c) . Images depict the dorsolateral lobes.
expression in different tissues is critically dependent on associated preneoplastic phenotype in the prostate. These cells demonstrated a high rate of proliferation that overcame the apoptotic survival signals and suggest a role for secondary cooperating effect of Myc expression, suggesting that prostate tissue conevents in rescuing cells from Myc-induced apoptosis.
tains survival factors that allow the cells to tolerate increased To determine the consequence of increased c-Myc expres-Myc protein. Microarray expression profiling studies defined a sion in the prostate, we generated transgenic mice expressing Myc prostate cancer expression signature that shares features human c-Myc from two different strength prostate-specific prowith human prostate cancer and implicates candidate genes moters. In all founder lines, Myc expression resulted in complete in tumor progression. For example, expression of the putative penetrance of mouse prostatic intraepithelial neoplasia (mPIN), human prostate tumor suppressor gene NXK3.1 (Bowen et al., which progressed to invasive adenocarcinoma within 6 to 12 2000; He et al., 1997; Voeller et al., 1997) was detected in Mycmonths of age. mPIN lesions were observed as early as 2 to 4 induced mPIN lesions but absent in invasive cancers. Furthermore, analysis of human cancer databases with the murine Myc weeks, providing evidence that Myc is sufficient to induce a gene signature uncovered gene clusters whose expression was previously shown to cooperate with Myc in mouse tumor models. Collectively, these findings define a novel transgenic mouse tightly correlated in human prostate, breast, and ovarian cancer. The murine Myc prostate tumor signature genes that are most model of prostate cancer and demonstrate the utility of comparing mouse and human cancer expression databases. consistently coexpressed in the human cancers included Pim-1, Figure 3 . Myc expression gives a proliferative advantage to prostate tissue A: Ki67 and TUNEL labeling revealed an increase in both proliferation and apoptosis as cells progress from wild-type (a and d) to mPIN (b and e) and finally to invasive cancer (c and f). Images of the dorsolateral lobes are shown. B: Proliferation increases as mice develop prostate cancer. A total of 500 cells were counted from five high-power fields and the number of Ki67-positive cells (proliferative index) was scored and graphed.
Results

Transgenic expression of Myc in the prostate induces mPIN, then invasive adenocarcinoma with reproducible kinetics and high penetrance
Two different prostate-specific transgenic expression constructs (probasin-Myc and ARR 2 /probasin-Myc) were used to vary the dosage of Myc expression specifically in the prostate ( Figure 1A) . Expression from the probasin promoter begins at a low level in the prostate at 1 to 2 weeks of age and increases with rising levels of androgen as the mice reach puberty between 4 and 8 weeks ( Figure 1B ). The ARR 2 /probasin promoter contains two additional androgen response elements, which boost the level of androgen-dependent expression ( Figure 1B ) (Wu et al., 2001; Zhang et al., 2000a) . Multiple founders were obtained for each construct (seven from the ARR 2 /probasin-Myc and three from the probasin-Myc), prostate-specific Myc protein expression was confirmed, and independent lines from each construct were expanded for phenotypic analysis. Based on the levels of transgene expression, the probasin-Myc mice and ARR 2 /probasin-Myc mice were designated Lo-Myc and Hi-Myc, respectively.
Mouse PIN (mPIN) is characterized histologically by the presence of multifocal proliferative lesions of atypical epithelial cells affecting several existing ductules within individual lobes. mPIN usually displays distinctive architectural growth patterns, e.g., cribiform and/or tufting, but these cells must also exhibit progressive nuclear atypia. Atypical cells are characterized by the presence of large irregular nuclei, exhibiting hyperchromatic or vesicular chromatin patterns, with prominent nucleoli and amphophilic cytoplasm. In both the Lo-Myc and Hi-Myc mice, multifocal proliferative lesions affecting several ductules within the individual lobes were observed in the dorsolateral (Figures 1Ck, 1Cl, 1Cp, and 1Cq) and ventral lobes and to a lesser extent in the anterior lobe. Cribiform and tufting growth patterns of the secretory epithelial layer were also observed ( Figures 1Ck, 1Cl , 1Cp, and 1Cq) as well as progressive nuclear atypia ( Figure 1C , 
cally atypical cells into the prostatic stroma and periprostatic
In each case, the anterior lobe was photographed. J: Table showing the vascular density (mm 2 ) in Hi-Myc and control littermates. adipose tissue. These acini exhibit crowding, irregular contours and haphazard growth patterns (Figures 1Co and 2Ab , 2Ae, and 2Af). The mPIN/cancer transition was evident by 3 to 6 months in all lobes of the Hi-Myc mice and by 10 to 12 months model for studying progression from mPIN to cancer and for in the Lo-Myc mice, suggesting that the dosage of Myc may preclinical therapeutic studies. affect the rate of disease progression (Figure 2A ). Invasion was To date, the only known murine models of prostate cancer confirmed by the absence of laminin and SMA staining, which that progress beyond the mPIN stage are the SV40 large T documents penetration through the basement membrane and antigen models of prostate cancer (TRAMP, C3-Tag, and LADY) the fibromuscular layer, respectively (Figures 2Bc and 2Bd ).
( Garabedian et al., 1998; Greenberg et al., 1995; Kasper et al. , Foci suggestive of lymphovascular invasion were also noted in 1998; Masumori et al., 2001; Shibata et al., 1996) . One potential some cancers (data not shown). mPIN was always found in shortcoming of the T antigen models is the high frequency of glands adjacent to the invasive tumor. The penetrance of mPIN neuroendocrine differentiation that occurs, as recognized by and cancer was essentially 100 percent in all founder lines with reliable kinetics (Table 1) , indicating the potential utility of this its typical histologic features and subsequent confirmation by immunohistochemical stains such as synaptophysin or chro-regulated by androgen, interpretation of the effect of hormone ablation must consider potential effects on expression of the mogrannin A ( Figure 2Cc ) (Masumori et al., 2001) . Although human prostate cancers can occasionally possess a completely transgene. Mice were either castrated at 2 months when they had definite mPIN lesions (n ϭ 3) or at 8 months (n ϭ 9) after neuroendocrine phenotype (e.g., small cell carcinoma), the majority do not. The mPIN and invasive carcinoma lesions detected tumors had developed, then analyzed either 1, 3, or 5 months post-castration ( Figure 5A ). All mice castrated at 2 months of in the Lo-Myc and Hi-Myc mice do not exhibit the morphologic features of neuroendocrine carcinomas, and this is further con-age have complete regression of mPIN within one month of castration (Figures 5Ba-5Bc ). This was correlated with absence firmed by the lack of immunostaining with synaptophysin ( Figure  2C , compare b and c). Therefore, the Lo-and Hi-Myc mice of detectable transgene expression by immunoblot ( Figure 5D ). This result indicates that Myc-induced mPIN is reversible, similar represent novel models for human prostatic adenocarcinoma that may offer advantages over current models.
to other Myc-induced neoplastic phenotypes in tetracyclineregulated models (Jain et al., 2002; Karlsson et al., 2003) . Similarly, all mice with prostate cancer (castrated at 8 months of Myc expression in the mouse prostate induces proliferation, apoptosis, and angiogenesis age) had histologic evidence of regression and fibrosis at all time points post-castration (Figures 5Bd-5Bl ). However, unlike Myc can induce proliferation, apoptosis, and angiogenesis in many cell types (Amati et al., 1998; Dang, 1999; mPIN lesions (Figures 5Ba-5Bc ), all these mice had residual tumor present even 5 months post-castration (Figures 5Bk and al., 2002a , 2002b Prendergast, 1999; Watnick et al., 2003) . To understand the cellular effects of Myc overexpression in the 5Bl). The residual tumors were apparently quiescent since we were unable to document proliferation of tumor cells by nuclear prostate, we first tested for proliferation using Ki67 immunohistochemistry and apoptosis using TUNEL assays. Immunohisto-Ki67 staining (Figures 5Ca and 5Cb ). Immunoblot studies showed loss of Myc expression in the residual tumors, indicating chemistry showed an increase in Ki67 staining in both mPIN and tumor lesions when compared to wild-type samples, as silencing of the transgene. Also, these tumors expressed lower levels of AR protein, a known consequence of castration (Figure shown in Figure 3A (d-f). Ki67 staining was quantified by counting a total of 500 cells. The proliferative index increased from 5D). Following castration, we also observed weak heterogenous expression of AR with predominately cytoplasmic localization, 20 in wild-type cells to 140 in mPIN lesions and 180 in tumor tissue ( Figure 3B ). TUNEL assays performed on the same tumor compared to nuclear localization in the intact mice ( Figure 5C , compare c and d). Collectively, these findings establish that AR showed that Myc was also capable of inducing apoptosis in the mouse prostate (Figures 3Aa-3Ac ). These results demon-is inactive and the Myc transgene is not expressed in these residual, post-castration tumors. The fact that these tumors fail strate that Myc induces both proliferation and apoptosis in the mouse prostate; however, the rapid development of mPIN sug-to fully regress, unlike the mPIN lesions, suggests that additional genetic events may have occurred that maintain tumor cell sur-gests that, like epidermal cells (Pelengaris et al., 1999) , the prostate may contain survival signals that rescue much of the vival. Larger cohorts of mice will be followed for longer time intervals to determine if these mice eventually relapse with pro-gland from Myc-induced apoptosis.
Myc can also induce angiogenesis in certain tissues, a prop-gressive, hormone refractory prostate cancer. erty that likely contributes to tumor progression and metastasis (Elenbaas et al., 2001; Hurlin et al., 1995; Pelengaris et al., 1999;  An expression signature for Myc-driven murine prostate cancer Watnick et al., 2003) . Therefore, we characterized changes in vascular density in the Hi-Myc tumor model at the mPIN and
The high penetrance and reliable kinetics of the PIN/cancer transition in these Myc models provides an experimental oppor-invasive cancer stages, using wild-type and transgenic animals at 2 and 12 months of age ( Figures 4A-4I ). Blood vessels were tunity to define the cooperating molecular events involved in Myc-driven prostate cancer progression. We isolated dorsal, identified in green after perfusion with FITC-conjugated Lycopersicum esculentum lectin as previously described (Rodriguez-lateral, ventral, and anterior prostate lobes from Hi-Myc transgenic mice and nontransgenic littermate controls at various time Manzaneque et al., 2001) . Increased vascular density was detected as early as 2 months in transgenic animals with mPIN points during the mPIN/cancer transition for gene expression profiling experiments. Samples were divided for parallel analysis ( Figures 4D-4F and 4J), and vascular density doubled with progression to invasive adenocarcinoma at the 12 month time point by mouse Affymetrix arrays for gene expression and comparative genome hybridization arrays (array CGH) for chromosomal ( Figures 4G-4I and 4J ). Vascular alterations, such as tortuosity and disorganization of vessels common to tumors, were noted at gains and losses. Matched tissue was saved for histological and immunohistochemical studies. The expression signatures 2 months and became significantly pronounced by 12 months.
Effects of hormone ablation on the initiation and
for wild-type and transgenic (mPIN and cancer combined) were strong enough to be recognized by unsupervised clustering with maintenance of Myc-induced prostate lesions Since hormone ablation therapy is the primary clinical treatment only one error ( Figure 6A ). Parallel array CGH experiments were also conducted using genomic DNA from these samples to for prostate cancer patients with advanced stage disease, we examined the effect of castration on disease progression in look for evidence of chromosomal gains or losses that might accompany these expression changes. To date, we have not the Hi-Myc transgenic mice. Since the ARR 2 PB promoter is D: Myc transgene expression is turned off and AR levels decrease following castration. Immunoblots of prostate lysates isolated from wild-type or transgenic intact (I) or castrate (C) mice were performed using the ␣-Myc (9E10) and ␣-AR antibodies. All mice showed a loss of Myc expression following castration as well as a decrease in AR levels. Actin serves as a loading control. observed any genomic changes in mPIN lesions or cancers, Additionally, the transgenic Myc gene list can include Myc transcriptional targets or genes whose up-or downregulation com-but it is important to note that current mouse BAC arrays are limited to 3 Mb resolution and we cannot rule out smaller gains plements Myc expression during tumorigenesis. Since the Myc transgene is expressed as early as 1 to 2 weeks of age, the or losses (data not shown).
Next we generated a supervised gene list that distinguishes transgenic Myc gene list can include genes directly or indirectly regulated by Myc transcription. In an attempt to address this wild-type mice from Myc transgenic mice. We ranked genes by the degree of differential expression between wild-type and issue, we compared our list of Myc-driven tumor-associated gene changes to various lists of Myc target genes and found transgenic mice using the Student's t test. The 60 most differentially expressed genes, excluding ESTs, are shown in Figure that some genes and gene families are in common, but we were unable to demonstrate any statistically significant overlap. Thus, 6B, and the complete list is available as Supplemental Data at http://www.cancercell.org/cgi/content/full/4/3/223/DC1. The not unexpectedly, our list does not appear to be dominated by direct Myc transcriptional targets. A better distinction between genes on this list can potentially come from several categories, including genes modulated generally in tumorigenesis (e.g., Myc primary and secondary target genes and genes more generally associated with prostate cancer will be possible by future from expansion of a particular cell type) or specifically in prostate tumorigenesis or Myc-driven tumorigenesis (Coller et al., 2000) .
comparison of the Myc-driven tumors to other mouse prostate cancer models (Wu et al., 2003 [this issue of Cancer Cell]). signature ( Figure 6B ) in a gene expression-based class predic-The substantial role of Myc in cellular proliferation (Gartel and tion analysis (Golub et al., 1999) , and then identified the genes Shchors, 2003; Sears and Nevins, 2002) raises the possibility most consistently differentially expressed between Myc-like and that the Myc prostate expression signature is strongly comnon-Myc-like human tumors and between wild-type and Myc prised of genes associated with proliferation. However, a comtransgenic mouse prostates ( Figure 7A , blue path) as follows: (a) parison of the Myc prostate signature with several previously
We began with our list of genes differentially expressed between published proliferation signatures did not show statistically sigwild-type and Myc transgenic mice. We then identified the hunificant overlap (Lam et al., 2001; Perou et al., 1999 ; Rosenwald man orthologs for these genes using the HomoloGene database et Whitfield et al., 2002) .
(http://www.ncbi.nlm.nih.gov/HomoloGene/) and determined Several genes of interest appeared on the list and include which were present in three human prostate cancer gene ex-L-Myc, normally expressed at high levels in differentiated prospression datasets. (b1) We ascertained whether the human tutate tissue (Luo et al., 2001) , Tmprss2, a serine protease overexmors were more Myc-like or non-Myc-like using a weighted pressed in a majority of prostate cancer patients (Vaarala et gene voting prediction algorithm (Golub et al., 1999) and then al., 2001), Sparc, an antiadhesive protein that is differentially (c) made ranked lists of the genes most differentially expressed expressed during human prostate cancer progression (Thomas between the human tumors in these two categories using the et al., 2000) , EGF, which has been implicated in prostate cancer Student's t test. Finally, (d) we identified the genes most consisprogression (Kim et al., 2003) , and several Ly6 genes that belong tently differentially expressed between Myc-like and non-Mycto the same family as prostate stem cell antigen (PSCA), a cell like human tumors based on the overlap between the ranked surface antigen overexpressed in human prostate cancer (Jalkut lists from the mouse and the three human datasets. In summary, and Reiter, 2002) ( Figure 6B , asterisks). We focused our attenthis method investigates whether the coexpressed mouse Myc tion on two genes, Nkx3.1 and Pim-1, for the reasons discussed prostate signature genes are also coexpressed in human canbelow ( Figure 6B, arrows) .
cers and identifies the most consistently regulated genes in the Myc prostate tumor expression module.
Loss of Nkx3.1 protein expression marks the transition
We first performed this analysis using three publicly available from mPIN to invasive cancer prostate cancer datasets ( (Table 2A , Figure 7B ). is a putative tumor suppressor gene in human prostate cancer Pim-1 was on our original list of genes differentially expressed (He et al., 1997) . Loss of heterozygosity at the Nkx3.1 locus between wild-type and Myc transgenic prostates with a rank of occurs commonly in human prostate tumors due to large dele-113 ( Figure 6B ; Supplemental Data on Cancer Cell website). tions at 8p22, but it has proved difficult to directly implicate
The reprioritization of Pim-1 to a rank of 1 is noteworthy, in that NXK3.1 as the relevant gene since mutations do not occur in Pim-1 has previously been shown to cooperate with Myc in the remaining allele (Voeller et al., 1997) . To distinguish between lymphomagenesis (van Lohuizen et al., 1989 (van Lohuizen et al., , 1991 , and sugthe possibilities that Nkx3.1 may be a Myc target gene (since gests that this approach could be used with other transgenic decreased Nkx3.1 mRNA levels were found in transgenic mice cancer models and human datasets to identify complementing with mPIN and cancer as compared to wild-type controls) versus oncogenes. a complementary secondary event, we examined Nkx3.1 protein To investigate whether the Myc expression signature identiexpression in situ using immunohistochemical studies. Nkx3.1 fied using our transgenic mice is prostate specific, we added protein expression was consistently present in mPIN lesions at breast and ovarian cancer datasets to our cross-species comvariable levels (Figures 6Cb and 6Cc ), but was undetectable in parison algorithm. We again found that one of the most consisall the cancers isolated from both the Hi-Myc and Lo-Myc strains tently regulated genes in the Myc expression module is Pim-1 (Figure 6Cd ). Immunoblot studies of prostate lysates from tu-(data not shown). This result is consistent with the fact that Myc mor-bearing mice also showed a marked decrease in Nkx3.1 expression is implicated in the progression of many tumor types protein expression when compared to lysates from wild-type (Nesbit et al., 1999) . or mPIN mice ( Figure 6D ). These results indicate that Nkx3.1
In the second method, we inferred the Myc status of the loss is distinct from the onset of Myc expression and raise human tumors based on whether their Myc expression level the possibility that Myc gain and Nkx3.1 loss may be critical was above or below the mean Myc expression level for the cooperating events in the mPIN/prostate cancer transition. dataset (step b2) and then followed the rest of the procedure outlined above ( Figure 7A, red path) . This procedure resulted Cross-species bioinformatic comparison of mouse in slightly different groupings of the human samples and accordand human datasets implicates Pim-1 in ingly a slightly different list of consistently modulated genes Myc-associated cancer progression (Table 2B) . It remains to be determined from independent data The large number of genes in the Myc prostate signature empha-(e.g., Myc gene amplification status of human tumors) whether sizes the need for strategies to prioritize genes for functional the predicted Myc status from the Myc mouse prostate tumor evaluation. Accordingly, we used two related methods to search signature or the inferred Myc status from the Myc expression for gene expression patterns common to both our Myc translevels better reflects the true Myc status of human tumors. gene model and human prostate cancer. A schematic of our However, both methods result in Pim-1 and GNAS1 (G protein, "cross-species expression module comparison" approaches is ␣ stimulating activity polypeptide 1) in the top 10 of the list of shown in Figure 7A .
consistently modulated genes. Additionally, this second method In the first method, we predicted the Myc status of the human tumors using the genes from the Myc mouse prostate revealed two other genes previously implicated in either prostate (Lasorella et al., 2001) .
tochemical results clearly demonstrate that Myc expression and Nkx3.1 loss are distinct events, separated in time during the Discussion mPIN/cancer transition. Of note, our finding appears distinct from the Nkx3.1 loss associated with PTEN loss in the accompa-The Myc transgenic models of prostate cancer described here nying paper (Wu et al., 2003) where reduced Nkx3.1 expression offer several advantages over current models in which the SV40 is coincident with PTEN loss, implying coordinate regulation in large T antigen serves as the initiating event. First, the histologic a single pathway. One compelling explanation for our result is features of the mPIN and cancer lesions accurately reflect the that loss of Nkx3.1 complements increased Myc expression to predominant adenocarcinoma phenotype observed in human promote the mPIN/cancer transition. Two additional findings prostate cancer, with no evidence for the neuroendocrine phesupport this hypothesis. First, comparative genomic hybridizanotype observed in many of the T antigen models (Masumori tion studies of human prostate cancer often report the parallel et Perez-Stable et al., 1997) . Second, the fact that presence of chromosome 8q24 gain (Myc) and 8p22 loss mPIN lesions appear with essentially 100 percent penetrance (Nkx3.1) in the same tumor (Tsuchiya et al., 2002) . Second, and progress to invasive cancer with reliable kinetics should Nkx3.1 knockout mice develop mPIN lesions but not cancer, make this model suitable for preclinical therapeutic studies. In suggesting that a rate-limiting second hit may be required for addition, the differences in progression time between the Lofull-blown tumorigenesis (Abdulkadir et al., 2002 ; Bhatia-Gaur Myc and Hi-Myc models provides some flexibility in the design Kim et al., 2002) . Alternatively, absence of Nkx3.1 of secondary genetic mouse crosses to study the effects of expression may be a marker for the cell of origin in the Myc complementing events. Finally, these mice show considerable and PTEN prostate cancer models and play no functional role improvement to the previously described Myc transgenic mouse in the transformation process. These and other hypotheses can driven by the C3 promoter. While the Myc transgenic mice driven now be tested through genetic crosses. by the PB and ARR 2 PB promoters develop mPIN and cancer,
In addition to examining our mouse prostate cancer gene the C3-Myc mouse fails to develop a similar phenotype, most lists for known human prostate cancer orthologs, we asked likely due to inadequate transgene expression (Zhang et al., whether the Myc prostate tumor signature can be observed in 2000b). a subset of human prostate cancers. Despite current limitations One notable feature of the mPIN lesions observed in our due to different microarray expression profiling platforms and models is their rapid onset relative to the timing of transgene the limited number of orthologs represented on mouse and expression. This raises the possibility that Myc is sufficient to induce preneoplastic lesions in the mouse prostate in the ab-human chips, we were able to verify that genes correlated with sence of any secondary changes, consistent with reports of Myc status in the mouse can be used to define Myc-like human Myc gene amplification in human PIN lesions (Bubendorf et al., tumors and that at least one of the genes most consistently 1999; Jenkins et al., 1997; Qian et al., 1997) . The latency for associated with the Myc prostate tumor signature in human disease onset in other transgenic Myc cancer models varies tumors, Pim-1, is consistent with our knowledge about the role widely and presumably reflects the availability of cooperating of Myc in tumorigenesis. Pim-1, a serine/threonine kinase, is survival signals, as seen in the skin versus pancreatic islet cell known to cooperate with Myc in murine lymphoma models models discussed previously (Pelengaris et al., 1999 (Pelengaris et al., , 2002b . (Moroy et al., 1991; van Lohuizen et al., 1989) , and increased Further work with an inducible Myc transgene is required to Pim-1 expression was recently observed in a subset of human directly address this question. Unfortunately, exogenously exprostate cancers and shown to correlate with poor clinical outpressed hormone-regulated Myc fusion genes cannot be used come (Dhanasekaran et al., 2001) . Although these investigators due to confounding effects of currently available inducing did not determine the Myc status of these tumors, our mouse agents such as tamoxifen on prostate cells. model and subsequent analysis of human microarray datasets There is optimism in the mouse modeling community that suggest that these genes are linked in prostate and other cancers. genetically engineered mouse models of human cancer will have While our initial analysis demonstrates the utility of crossutility in the preclinical evaluation of new anticancer agents, species comparisons of global datasets, a number of steps perhaps serving as better predictors of clinical activity in huneed to be taken to realize the full potential of this approach. mans. We explored this question using hormone ablation ther-It will be important to standardize expression analysis platforms apy, a conventional treatment approach for advanced prostate to provide comprehensive coverage of the mouse and human cancer. The initial results establish that mPIN lesions are comtranscriptome with appropriate cataloguing of orthologs for pletely reversible whereas advanced adenocarcinomas undergo cross comparison. In addition, human datasets must be linked partial regression. Further studies are needed to determine if to independent tissue analysis for specific molecular lesions of mice with residual, apparently quiescent lesions eventually reinterest, such as Myc amplification or PTEN loss for the examlapse with full-blown hormone refractory prostate cancer. It will ples discussed here. Parallel construction of tissue arrays from also be of interest to determine why these advanced lesions, tumor samples analyzed by expression microarrays will allow unlike mPIN, are not fully reversible despite silencing of the such experiments to be performed. Ultimately, we envision ustransgene.
ing such cross-species comparisons to validate the relevance Another desired characteristic of mouse cancer models is of mouse models for human disease, to help prioritize lengthy that they recapitulate the molecular features of the human disgene lists for functional evaluation, and to extend lists of gene ease. Mouse-specific genomics tools for expression profiling cohorts that segregate with a specific molecular lesion across allowed us to address this question using a global approach. Among the most interesting initial findings was reduced expres-multiple tissues.
Experimental procedures and sterile dissecting shears were used to make a 4-5 mm incision in this region. Using two sterile forceps, the testes were located and a ligature was made around the testicular vessels and the tunica albugenea that encases Plasmids The plasmids ARR 2 PB-Flag-Myc-PAI and PB-Flag-Myc-PAI were con-the testes. The testes were amputated with dissecting shears and the scrotum sutured shut with 6-0 Ethilon black monofilament nylon (Ethicon Inc., structed by ligation of the following gene fragments into the Bluescript (KSϩ) backbone (Stratagene). For PB-Flag-Myc-PAI: the poly(A) tail of the insulin 1665). A local triple antibiotic was applied over the region of the wound to facilitate healing. receptor gene (PAI) was subcloned into the BamHI/NotI site of the bluscript KSϩ multiple cloning site (MCS). The 5Ј flanking promoter region (Ϫ426/ ϩ28) of the rat probasin gene was subcloned into the KpnI/EcoRV restriction Pathological and immunohistochemical data sites located in the MCS. The human Myc c-DNA was amplified by PCR Mice were aged to the appropriate time point and then sacrificed for dissection. The prostate tissues that were sent for histology were marked with ink using a 5Ј primer containing the BglII restriction site and the consensus on one side (the cut side), splayed, and embedded "en face" to maximize sequence for the FLAG epitope (5ЈGGGAGATTCTCATCGCCACCATGGAC pathologic examination of each lobe. Sections were cut in the same manner TACAAGGACGACGACGACAAGGCCATGCCCCTCAACGTTAGCTTCACC).
on the microtome, enabling us to orient the prostatic lobes with the bladder The epitope tag was engineered to aid with immunohistochemistry; however, and the seminal vesicles as a reference point. Prostates, testes, lung, liver, we were unable to detect it via Western blot (data not shown) and relied on bone (spine), kidney, and brain were all harvested for Western blot analysis the human-specific anti-9E10 Myc antibody (Santa Cruz) to detect transgene and histology. The tissues that were kept for protein analysis were homogeexpression. The 3Ј primer contained a BamHI restriction site for cloning nized using a tissue grinder in 2ϫ SDS buffer (100 mM Tris-Hcl pH ϭ 6.8, purposes (3ЈGGGGGATCCTTACGCACAAGAGTTC CGTAGCTGTTC). After 200 mM DTT, 4% SDS, 20% glycerol, 50 mM B-gly-Phosphate, 1 mM PCR amplification, the product was gel purified, digested, and filled in using NaVo4, and 40 g/ml PMSF) and normalized for total protein via Bio-Rad the large fragment Klenow polymerase. Following gel purification, the bluntassay. Tissue used for histology was fixed initially in 10% buffered formalin ended product was subcloned into the EcoRV site of the bluescript KSϩ phosphate (Fisher SF100-4) for 8 hr followed by gentle washing in running PB-PAI backbone, thus generating the PB-Flag-Myc-PAI transgenic conwater and finally transferred to 70% ethanol. Serial tissue sections (4 m struct. The ARR 2 PB-Flag-Myc-PAI was generated in the same way except thick) were cut from paraffin-embedded blocks and placed on charged glass that the ARR 2 PB promoter sequence was subcloned into the KpnI/EcoRV slides. H&E and masson trichrome staining were performed using standard site instead of the PB promoter. The ARR 2 PB sequence contains the original procedures. For immunohistochemical analysis using polyclonal antibodies, probasin sequence PB (Ϫ426/ϩ28) plus two additional androgen response the Vector Laboratories R.T.U. Vectastain Universal Elite ABC Kit (cat# PKelements (Zhang et al., 2000a) . The completed constructs were sequenced 7200) was used, and for monoclonal antibodies, we used the Vector M.O.M. and tested for promoter inducibility by androgen in LNCaP cells by transient Basic Kit (BMK-2202). Briefly, sections were deparaffinized with xylene and transfection before microinjection into FVB ova. By transient transfection, rehydrated through graded alcohol washes followed by antigen retrieval in the ARR 2 PB promoter was able to confer approximately 20ϫ higher levels a pressure cooker for 30 min in sodium citrate buffer (10 mM, pH 6.0). Slides of expression than the PB promoter (data not shown).
were then incubated in 0.3% hydrogen peroxide to quench endogenous horseradish peroxidase for 30 min. The slides were then blocked by incuba-Generation of transgenic ARR 2 PB-Myc-PAI and PB-Myc-PAI mice tion in normal horse serum (dilution 1:20) in 0.1 M Tris-buffered saline (pH The ARR 2 PB-Myc-PAI and PB-Myc-PAI constructs were linearized with KpnI/ 6.0) and subsequently incubated for 30 min with the following antibodies NotI, microinjected into fertilized FVB ova, and transplanted into a pseudodiluted in Tris-buffered saline: anti-synaptophysin polyclonal antibody (Dako pregnant female (University of Irvine Transgenic Facility). Transgenic found-# A0010) diluted (1:5000), anti-␣ smooth muscle actin monoclonal antibody ers were screened by PCR using genomic DNA isolated from tail snips. The (Dako # M0851) diluted (1:1000), anti-Nkx3.1 polyclonal antibody (kindly 5Ј primer was specific to either the ARR 2 PB promoter (5ЈARR 2 PB-CAATGTC provided by Dr. Cory Abate-Shen) diluted (1:6000), anti Ki67 polyclonal TGTGTACAACTGCCAACTGGGATGC) or the PB promoter (5ЈPB-CCGGT antibody (Novacastra Laboratories #NCL-Ki67p) diluted (1:20,000), anti-CGACCGGAAGCTTCCACAAGTGCATTTA), and the 3Ј primer for both reacandrogen receptor polyclonal antibody (Upstate # 06-680) diluted (1:100), tions was located at the end of the Myc cDNA (5ЈTTACGCACAAGAGTTC anti-laminin polyclonal antibody (Sigma # L-9393) diluted (1:300). Negative CGTAGCTGTTC). A PCR product of 1438 base pairs was generated from controls were included in each assay. Slides were then treated with biotinthe ARR 2 PB-Myc-PAI mice and a 1774 base pair product was produced by labeled anti-mouse IgG and incubated with preformed avidin biotin peroxithe PB-Myc-PAI mice. Seven founder lines were obtained from the ARR 2 PBdase complex. Metal enhanced diaminobenzidine substrate was added in Myc-PAI construct (designated 1, 2, 4, 7, 8, 11, and 13) whereas three the presence of horseradish peroxidase, and finally, sections were counterfounders were generated with the PB-Myc-PAI construct (designated # 6, stained with hematoxylin, dehydrated, and mounted. 9, 10). Breedings were carried out and germline transmission was obtained by four ARR 2 PB-Myc-PAI founders (4, 7, 11, and 13) and two PB-Myc-PAI mice (6 and 9). These mice were bred and the offspring were aged to TUNEL assays TUNEL assays were performed as described in the In Situ Cell Death Detec-determine if prostate cancer developed in the transgene-positive male mice. Prostates were isolated "en block" from transgenic and wild-type mice at tion Kit, POD from Roche. Prior to the addition of TdT enzyme, sections were deparaffinized with xylene and rehydrated through graded alcohol 2 to 12 weeks as well as at 6, 9, 12, and 16 months and cut in half along the saggital plane. Superficial and deep H&E sections were examined on washes. Antigen retrieval was performed in sodium citrate buffer (10 mM, pH 6.0) by applying microwave irradiation (750 W) for 1 min. The slides where the same tissue in order to document the presence/absence of mPIN, microinvasion, and invasive adenocarcinoma (described below).
then incubated for 5 min in 3% hydrogen peroxide to quench endogenous horseradish peroxidase. Next, slides were immersed for 30 min at room temperature in Tris-HCl, 0.1 M, pH ϭ 7.5 containing 3% BSA and 20% Mouse dissections, tissue isolation, and castration normal bovine serum. TUNEL reaction mixture containing a 1:20 dilution of Urogenital organs were isolated and prostates were microdissected in a TdT enzyme was added to the slides for 2 hr at 37ЊC in a humidified atmopetri dish containing 10 ml of cold phosphate-buffered saline (1ϫ PBS, sphere chamber. Fifty microliters of Converter-POD was then added to each Gibco-BRL 14190144) under a dissecting microscope. Adipose tissue surslide and incubated at 37ЊC for 45 min in a humidified atmosphere chamber. rounding the mouse prostates was cleared using forceps. The mouse pros-DAB substrate was applied for 1 min followed by counterstaining in hematate is composed of four pairs of lobes (ventral, dorsal, lateral, and anterior toxylin. lobes), which were separated from the urethra using dissecting shears. One half was used to obtain protein and RNA while the other half was fixed in 10% phosphate-buffered formalin for histology (Fisher SF100-4). The liver, Evaluation of the vasculature For visualization of vessels, mice received an intravascular injection of fluores-testes, bone from the spine, brain, kidneys, and lungs were also isolated for both histological examination as well as protein analysis to check for cein isothiocyanate (FITC) labeled Lycopersicon esculentum lectin (1 mg/kg, Vector, Burlingame, California). This lectin binds to the luminal surface of murine nonspecific expression of Myc. For castration experiments, mice were anesthetized using Isoflurane (Abbott Laboratories). The perineal region was vasculature. Five minutes later, the animals were fixed by perfusion of 1% paraformaldehyde in phosphate-buffered saline (pH 7.3) at a pressure of 120 cleaned three times with ethanol and a betadine scrub (VWR, AJ159778), mm Hg using a cannula in the left ventricle. Prostates were subsequently To determine the number of genes to use in the weighted gene voting dissected and either mounted directly on glass slides (2 month prostates) or algorithm (step b1), we used a consistency requirement. This is necessary embedded (12 month prostates) in low melting point agarose (BioWhittaker since the weighting factor is not perfect and using too many genes results Molecular Applications, Rockland, Maine) and cut at 200 m sections with in the incorporation of noise. In summary, for all possible values of n (from a Vibratome (The Vibratome Company, St. Louis, Missouri) . Sections were 1 to the total number of orthologs), we used n genes to make the Myc-like subsequently mounted onto glass slides using anti-fade media (Vectashield, and non-Myc-like assignments. In each case, we then determined what Vector, Burlingame, California) in the presence of Topo3 dye (Molecular fraction of these n genes are significantly differentially expressed (p Ͻ 0.1) Probes, Oregon) for visualization of nuclei and examined with a BioRad1024 between the two groups (i.e., the fraction of individual genes that voted confocal microscope (BioRad, Hercules, California). Evaluation of vascular consistently with the consensus [summed] vote of all n genes). Then for the density was performed on a Nikon Diaphot 300 microscope equipped with final predictions, we used the value of n for which this fraction was maximal. a Toshiba 3CCD camera. Number of vessels per 250 m square was ob-Applying this procedure individually to each dataset, the number of genes tained by using IMAGEPRO 4.0 software (Media Cybernetics, Silver Spring, used in the weighted gene voting algorithm ranged from 10 to 50. Maryland). To achieve comprehensive sampling, three independent animals Since the different human datasets were collected using different gene were evaluated per age. Ten images of 250 m each were assessed per microarrays with different genes present, the human orthologs used in the animal. Statistical significance was assessed by Student's t test.
weighted gene voting varied between datasets. It is also noteworthy that from the genes used in the predictions, chosen only by their expression Microarray measurements patterns in the mouse data, only one (Hs.84775) ended up on the top 10 Total RNA was isolated from gross prostate tissue following microdissection list of genes most consistently modulated in all datasets (Table 2A ). using the Tri-Reagent RNA Isolation Reagent (Sigma-Aldrich cat# T9424) as
In the second method (red path), (b2) we first inferred the Myc status described by the manufacturer. Biotin-labeled cRNA was generated followof human tumors based on their relative Myc expression levels, assigning ing Affymetrix protocols. Briefly, first strand cDNA synthesis was carried out the tumors to one of two groups, Hi-Myc or Lo-Myc, based on whether their by reverse transcribing total RNA using Superscript Reverse Transcriptase Myc expression level was above or below the mean Myc expression level (Gibco cat# 18064-014). Second strand synthesis was performed using 10 for the dataset. Again, we preformed this step individually for each human U/l DNA ligase (Gibco cat# 18052-019), 10 U/l DNA Pol I (Gibco cat# dataset. Steps c and d were then carried out as above. For human dataset C, 18005-025), and 2 U/l RNase H (Gibco cat# 18021-014). Double-stranded we only used samples with similar overall microarray hybridization intensities cDNA cleanup was done using the GeneChip Sample Cleanup Module (Affy-(scale factors between 0.7 and 1.4) (Singh et al., 2002) . metrix cat# P/N 900371). Synthesis of biotin-labeled cRNA was carried out using the Enzo Bioarray Kit (Enzo Diagnostics Inc. cat# 42655-20) and,
